Novartis (NVS) Projected to Announce Earnings on Tuesday

Novartis (NYSE:NVS) is expected to issue its Q2 2026 results before the market opens on Tuesday, July 21st. Analysts expect Novartis to announce earnings of $2.17 per share and revenue of $14.1614 billion for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, July 21, 2026 at 11:40 AM ET.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The company had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same period last year, the business posted $2.28 earnings per share. On average, analysts expect Novartis to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Novartis Stock Down 0.5%

NVS opened at $153.35 on Tuesday. Novartis has a 12 month low of $112.34 and a 12 month high of $170.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The business’s 50-day moving average price is $150.96 and its 200-day moving average price is $151.32. The company has a market cap of $292.62 billion, a P/E ratio of 21.97, a P/E/G ratio of 2.65 and a beta of 0.45.

Institutional Trading of Novartis

Institutional investors have recently modified their holdings of the company. Brighton Jones LLC increased its holdings in Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after purchasing an additional 2,666 shares during the period. AQR Capital Management LLC lifted its holdings in Novartis by 102.8% in the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after buying an additional 11,444 shares during the period. Empowered Funds LLC purchased a new stake in Novartis in the 1st quarter worth approximately $1,764,000. Sivia Capital Partners LLC lifted its holdings in Novartis by 48.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock worth $963,000 after buying an additional 2,581 shares during the period. Finally, Schnieders Capital Management LLC. bought a new stake in shares of Novartis in the 2nd quarter worth approximately $202,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Sanford C. Bernstein upgraded Novartis to a “hold” rating in a research report on Thursday, March 19th. Finally, Morgan Stanley boosted their price objective on Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.